Lamotrigine Deprescribing from 400mg in Bipolar Type II
Taper lamotrigine by 50-100 mg every 1-2 weeks, extending the taper over 8-16 weeks to minimize risk of mood destabilization and withdrawal symptoms.
Recommended Tapering Schedule
For a patient on 400 mg daily, implement the following gradual reduction:
- Week 1-2: Reduce to 300 mg daily
- Week 3-4: Reduce to 250 mg daily
- Week 5-6: Reduce to 200 mg daily
- Week 7-8: Reduce to 150 mg daily
- Week 9-10: Reduce to 100 mg daily
- Week 11-12: Reduce to 50 mg daily
- Week 13-14: Reduce to 25 mg daily
- Week 15-16: Discontinue
This schedule provides decrements of approximately 12-25% every 1-2 weeks, which aligns with general psychotropic tapering principles 1, 2.
Critical Monitoring Requirements
Watch for depressive relapse: Lamotrigine is specifically effective at preventing depressive episodes in bipolar disorder 3, 4, 5. The risk of depressive recurrence increases substantially after discontinuation, particularly in bipolar II patients where depression dominates the clinical picture 6, 4.
Monitor weekly during the taper for:
- Emerging depressive symptoms (anhedonia, sleep changes, suicidal ideation)
- Mood instability or rapid cycling
- Anxiety or irritability (potential withdrawal symptoms)
- Any hypomanic symptoms (though less common in bipolar II)
Special Considerations for Bipolar Type II
Bipolar II patients are at particularly high risk for depressive relapse when discontinuing lamotrigine, as this medication's primary benefit is depression prevention rather than antimanic effects 3, 7, 4. Studies show 50-83% response rates in treatment-resistant bipolar depression 8, and maintenance treatment significantly reduces relapse rates compared to placebo 4.
If the patient has predominantly depressive episodes or treatment-resistant depression, strongly reconsider whether discontinuation is appropriate. The evidence suggests lamotrigine may be one of the most effective maintenance treatments for this population 7, 4, 5.
Adjustments Based on Concomitant Medications
If the patient is taking valproic acid: The effective dose of lamotrigine is already reduced (typically 100 mg instead of 200 mg due to pharmacokinetic interactions). Taper more conservatively with 25 mg decrements every 2 weeks 3.
If the patient is taking enzyme inducers (carbamazepine, phenytoin): The 400 mg dose may represent a lower effective concentration. Consider slightly faster tapering if tolerated, but maintain close monitoring 9, 3.
Managing Withdrawal and Relapse Risk
Unlike some psychotropics, lamotrigine does not typically cause acute withdrawal syndromes, but mood destabilization is the primary concern 2. The gradual taper allows early detection of emerging symptoms before full relapse occurs.
If depressive symptoms emerge during taper:
- Pause the taper at the current dose for 2-4 weeks
- If symptoms persist or worsen, return to the previous stable dose
- Reassess the necessity of discontinuation with the patient
Alternative strategy if discontinuation is essential: Consider cross-tapering to another mood stabilizer with maintenance efficacy (lithium or valproate) rather than complete discontinuation 10, 11, 5.
Common Pitfalls to Avoid
Do not taper too rapidly. While lamotrigine doesn't cause benzodiazepine-like withdrawal, rapid discontinuation increases relapse risk substantially. The 8-16 week timeline balances safety with practicality 1, 2.
Do not assume stability means the medication isn't working. Patients stable on lamotrigine for extended periods may have forgotten their pre-treatment symptom severity. Review the original indication and treatment response before proceeding 2.
Do not discontinue during high-stress periods. Time the taper during periods of relative life stability to minimize confounding factors that could trigger mood episodes independently.
Post-Discontinuation Monitoring
Continue monitoring for at least 6 months after complete discontinuation, as depressive episodes may emerge weeks to months after the last dose 2. This protracted timeline reflects lamotrigine's mechanism in preventing rather than acutely treating mood episodes 3, 4.